

Update Notes

This is a correction of the Toxicology 2026 update dated 6/26/2026. The corrected update now includes the inactivated tests that the new tests are replacing.

Update Summary

New Test Activation	7/28/2026	PN04C - "Drug Screen, Pain Management Panel 4"
Inactivate Test With Replacement	8/25/2026	PETCB - "Phosphatidylethanol Confirmation, Blood" replaced by PETHC - "Phosphatidylethanol, Blood"
Inactivate Test With Replacement	8/25/2026	UGABA - "Gabapentin, Urine" replaced by UCGAB - "Clin Urine Gabapentin Confirm"
Inactivate Test With Replacement	8/25/2026	UMPDM - "Methylphenidate and Metabolite, Urine" replaced by UCMPD - "Clin Urine Methylphenidate and Ritalinic Acid Confirm"
Inactivate Test With Replacement	8/25/2026	UPREG - "Pregabalin, Urine" replaced by UCPGL - "Clin Urine Pregabalin Confirm"

New Test Activation

Effective Date	7/28/2026
Name	Drug Screen, Pain Management Panel 4
Code	PN04C
CPT Code(s)	80307, 80355 (G0480), 80366 (G0480), 80360 (G0480)
Notes	New York DOH Approval Status: No

Specimen Requirements

Specimen Required	<i>Collect:</i> Random urine <i>Specimen Preparation:</i> 30.0 mL urine in a screw capped plastic urine container. Newborn minimum requires 2.5 mL urine for the initial test and 0.5-5.0 mL for positive confirmations. <i>Minimum Volume:</i> 15.0 mL <i>Transport Temperature:</i> Refrigerated
Rejection Criteria	Urine catheter cup (with needle). Samples received at room temperature.
Stability	Room temperature: Unacceptable Refrigerated: 14 days Frozen: 30 days

Performing Information

Methodology	Enzyme Immunoassay; Gas Chromatography/Mass Spectrometry; Liquid Chromatography/Mass Spectrometry/Mass Spectrometry
Reference Range	See report
Performed Days	Monday - Friday
Turnaround Time	2 - 6 days
Performing Laboratory	Warde Medical Laboratory

Interface Information

Legacy Code	PN04C		
Interface Order Code	3000394		
Result Code	Name	LOINC Code	AOE/Prompt
1846080	Amphetamine Screen	3349-8	No
1846090	Confirm for Amphetamine	16234-7	No
1846100	Confirm for Methamphetamine	16235-4	No
1846110	Confirm for MDA	20545-0	No
1846120	Confirm for MDMA	18358-2	No
1846130	Confirm for MDEA	45143-5	No
1848900	Barbiturate Screen	3377-9	No
1848905	Confirm for Amobarbital	16239-6	No
1848910	Confirm for Butabarbital	16236-2	No
1848915	Confirm for Butalbital	16237-0	No
1848920	Confirm for Pentobarbital	16240-4	No
1848950	Confirm for Phenobarbital	16241-2	No
1848955	Confirm for Secobarbital	16238-8	No
1848960	Benzodiazepine Screen	3390-2	No

1848965	Confirm for Alprazolam	59615-5	No
1848970	Confirm for Clonazepam	16229-7	No
1848975	Confirm for Flurazepam	16231-3	No
1848980	Confirm for Lorazepam	17088-6	No
1848985	Confirm for Nordiazepam	16228-9	No
1848990	Confirm for Oxazepam	16201-6	No
1848995	Confirm for Temazepam	20559-1	No
1849250	Buprenorphine Screen	3414-0	No
1849260	Confirm for Buprenorphine	49752-9	No
1849270	Confirm for Norbuprenorphine	49751-1	No
1847060	Cocaine Screen	3393-6	No
1847070	Confirm for Cocaine	16226-3	No
1849005	Ethanol Screen	5644-0	No
1849010	Confirm for Ethanol	34180-0	No
3000966	Ethyl Glucuronide Screen	79239-0	No
3000967	Ethyl Sulfate	60676-4	No
3000968	Ethyl Glucuronide	45324-1	No
1828410	Fentanyl	58379-9	No
1839220	Confirm for Fentanyl	58381-5	No
1839240	Confirm for Norfentanyl	58383-1	No
3000464	Gabapentin	59680-9	No
1828510	Meperidine	58385-6	No
1838120	Confirm for Meperidine	16253-7	No
1838140	Confirm for Normeperidine	58389-8	No
1849280	Methadone Screen	3773-9	No
1849290	Confirm for Methadone	16246-1	No
1849285	Confirm for EDDP	58429-2	No
3000466	Methylphenidate	3809-1	No
3000467	Ritalinic Acid	33507-5	No
1847480	Opiate Screen	3879-4	No
1847510	Confirm For Morphine	16251-1	No
1847520	Confirm For Codeine	16250-3	No
1848530	Confirm For Hydrocodone	16252-9	No
1847540	Confirm For Hydromorphone	16998-7	No
1847550	Confirm For Oxycodone	16249-5	No
1847560	Confirm For Oxymorphone	17395-5	No
1847810	Phencyclidine Screen	3936-2	No
1847820	Confirm for Phencyclidine	3937-0	No
3000468	Pregabalin	105953-4	No
1849310	Propoxyphene Screen	19141-1	No
1849320	Confirm for Propoxyphene	16242-0	No
1848020	THC Screen	3427-2	No
1848030	Confirm for THC	20521-1	No
1848040	THC/CR Ratio	13478-3	No
1837210	Tramadol	19710-3	No

1823520	Confirm for Tramadol	20561-7	No
1823540	Confirm for O-desmethyiltramadol	86453-8	No
1849330	Creatinine	2161-8	No
1849340	Adulterant	59061-2	No
3000969	See Below		No



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000073111 F 02/15/1985

Collected: 06/26/2026 13:37

Received: 06/26/2026 13:37

Drug Screen, Pain Management Panel 4

Test Name	Result	Flag	Ref-Ranges	Units	Site
Amphetamine Screen	Negative		Negative		WMRL
Barbiturate Screen	Negative		Negative		WMRL
Benzodiazepine Screen	Negative		Negative		WMRL
Buprenorphine Screen	Negative		Negative		WMRL
Cocaine Screen	Negative		Negative		WMRL
Ethanol Screen	Negative		Negative		WMRL
Ethyl Glucuronide Screen	Positive		Negative		WMRL
Ethyl Sulfate	>100000.00	H	Negative	ng/mL	WMRL
Ethyl Glucuronide	>100000.00	H	Negative	ng/mL	WMRL
Decision Limit by LC/MS/MS					

Drug Analyzed	Confirmation	Units
-----	-----	-----
Ethyl Glucuronide	500	ng/mL
Ethyl Sulfate	200	ng/mL

Consumption of 30 to 33 fl. oz. of beer: (4.2 percent w/v) can result in urinary ethyl glucuronide concentrations of 22,000 to 67,000 ng/mL at 3 hours.

Ethyl glucuronide can be routinely quantified in urine for about 20 hours after a single drink of an ethanol containing beverage (up to 80 hours after heavy ethanol consumption).

Both ethyl glucuronide (ETG) and ethyl sulfate (ETS) are metabolites of ethanol. Detection of ETS confirms that the presence of ETG is not a result of in vitro fermentation of sugars. It is known that bacterial fermentation would generate ETG in vitro, but not ETS. Under normal situation, detection of both metabolites concurrently after alcohol consumption is likely. However, due to the genetic polymorphism in the general population, and/or the timing of the specimen collection after drinking, detection of only one metabolite, either ETG or ETS is possible.

MRO evaluation is recommended for forensic issues.

Fentanyl	Negative	Negative	WMRL
----------	----------	----------	------

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,

Report Date: 06/26/2026 13:50

D826001276 Ordered By: CLIENT C CLIENT,

WMB-26-367193

WX0000073111 WX00000000409391

Page 1 of 3

Kajal V. Sitwala, MD, PhD - Medical Director



LABORATORY REPORT

Example Client, XYZ123

1234 Warde Road

Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000073111 F 02/15/1985

Test Name	Result	Flag	Ref-Ranges	Units	Site
Gabapentin	Negative		Negative	µg/mL	WMRL
Meperidine	Negative		Negative		WMRL
Methadone Screen	Negative		Negative		WMRL
Methylphenidate	Negative		Negative	ng/mL	WMRL
Ritalinic Acid	Negative		Negative	ng/mL	WMRL
Opiate Screen	Negative		Negative		WMRL
The opiate screen interpretation result includes immunoassay screen tests for both general opiates and oxycodone.					
Phencyclidine Screen	Negative		Negative		WMRL
Pregabalin	Negative		Negative	µg/mL	WMRL
Propoxyphene Screen	Negative		Negative		WMRL
THC Screen	Negative		Negative		WMRL
Tramadol	Negative		Negative		WMRL
Creatinine	76		20-250	mg/dL	WMRL
Adulterant	Negative				WMRL
See Below	See Below				WMRL

Decision Limits

	Screen Cutoff Conc.	Confirm Cutoff Conc.
Amphetamine	500 ng/mL	(LC/MS/MS) 100 ng/mL
Barbiturates	200 ng/mL	(GC/MS) * ng/mL
Benzodiazepines	100 ng/mL	(LC/MS/MS) * ng/mL
Buprenorphine	5 ng/mL	(LC/MS/MS) 5 ng/mL
Cocaine	150 ng/mL	(LC/MS/MS) 30 ng/mL
Ethanol	20 mg/dL	(GC/FID) 20 mg/dL
Ethyl Glucuronide	500 ng/mL	(LC/MS/MS) * ng/mL
Fentanyl	2 ng/mL	(LC/MS/MS) 1 ng/mL
Gabapentin	**	(LC/MS/MS) 0.5 µg/mL
Meperidine	200 ng/mL	(LC/MS/MS) 5 ng/mL
Methadone	150 ng/mL	(LC/MS/MS) 100 ng/mL
Methylphenidate	**	(LC/MS/MS) 50 ng/mL
Ritalinic Acid	**	(LC/MS/MS) 50 ng/mL
Opiates	300 ng/mL	(LC/MS/MS) 25 ng/mL
Oxycodone	100 ng/mL	(LC/MS/MS) 25 ng/mL
Phencyclidine	25 ng/mL	(LC/MS/MS) 5 ng/mL
Pregabalin	**	(LC/MS/MS) 0.5 µg/mL
Propoxyphene	300 ng/mL	(LC/MS/MS) 60 ng/mL
THC (Cannabis)	25 ng/mL	(GC/MS) 3 ng/mL
Tramadol	200 ng/mL	(LC/MS/MS) 5 ng/mL

* Decision limit depends on drug detected.

** No immunoassay available.

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,

D826001276

Ordered By: CLIENT C CLIENT,

WX0000073111

WX00000000409391

Report Date: 06/26/2026 13:50

WMB-26-367193

Page 2 of 3

Kajal V. Sitwala, MD, PhD - Medical Director



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000073111 F 02/15/1985

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
------------------	---------------	-------------	-------------------	--------------	-------------

Adulterant Decision Limit:
General Oxidants 200 ug/mL

The adulterant assay tests for General Oxidants, including Chromates and Nitrites. Adulterants are substances either ingested or added directly to a urine specimen to prevent the detection of drug use.

If applicable, any drug confirmatory testing by LCMSMS/GCMS and the benzodiazepine screening were developed at Warde Medical Laboratory. While the performance characteristics have been fully evaluated and validated using appropriate protocols, this benzodiazepine screening test and all confirmatory tests have not been cleared or approved by the FDA. Warde Laboratory is regulated under CLIA as qualified to perform high complexity testing. These tests is for patient testing and should not be interpreted for investigation or research purposes.

Performing Site:

WMRL: Warde Medical Laboratory 300 West Textile Road Ann Arbor MI 48108 (800)876-6522

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,
D826001276 Ordered By:CLIENT C CLIENT,
WX0000073111 WX00000000409391

Report Date: 06/26/2026 13:50

WMB-26-367193

Page 3 of 3

Kajal V. Sitwala, MD, PhD - Medical Director

Inactivate Test With Replacement

Effective Date	8/25/2026
-----------------------	-----------

Inactivated Test

Name	Phosphatidylethanol Confirmation, Blood
Code	PETCB
Legacy Code	PETCB
Interface Order Code	3800363

Replacement Test

Name	Phosphatidylethanol, Blood
Code	PETHC
CPT Code(s)	80321 (G0480)
Notes	New York DOH Approval Status: No

Specimen Requirements

Specimen Required	<i>Collect:</i> Lavender EDTA <i>Specimen Preparation:</i> Send 1.0 mL whole blood in the original tube. Do not aliquot. Do not centrifuge. Do not use alcohol to clean arm. Use alternatives such as Betadine to cleanse arm before collecting any specimen. <i>Minimum Volume:</i> 0.5 mL <i>Transport Temperature:</i> Refrigerated
Rejection Criteria	Gross lipemia, Gross icterus, Serum separator tube (SST), Red top, not in original collection tube
Stability	Room temperature: Unacceptable Refrigerated: 14 days Frozen: 28 days

Performing Information

Methodology	Liquid Chromatography - Tandem Mass Spectrometry
Reference Range	Negative (<10 ng/mL)
Performed Days	Tuesday, Thursday
Turnaround Time	4 - 6 days
Performing Laboratory	Warde Medical Laboratory

Interface Information

Legacy Code	PETHC		
Interface Order Code	3000971		
Result Code	Name	LOINC Code	AOE/Prompt
3000972	POPETH (16:00/18.1)	97607-6	No
3000973	PLPETH (16:00/18.2)	97606-8	No



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000073111 F 02/15/1985

Collected: 06/26/2026 15:09

Received: 06/26/2026 15:09

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
POPETH (16:00/18.1)	50		Negative	ng/mL	WMRL
POPETH Interpretation					

<10 ng/mL: Negative

10-19 ng/mL: Abstinence or light alcohol consumption;
<2 drinks per day for several days a week.

20-200 ng/mL: Moderate alcohol consumption;
2-4 drinks per day for several days a week.

>200 ng/mL: Heavy alcohol consumption;
>4 drinks per day, chronically or several days per week.

Reference: W. Ulwelling and K. Smith, Journal of Forensic
Science, 2018, Vol 63, Pages 1634-1640

PLPETH (16:00/18.2)	Negative	Negative	ng/mL	WMRL
PLPETH Interpretation				

<10 ng/mL: Negative

Numerical values for PLPEth corresponding to the degree of alcohol
consumption have not been established.

Additional information:

Phosphatidylethanol (PEth) is a group of phospholipids formed on a
glycerol backbone by various combinations of fatty acids on the
erythrocyte membrane. POPETH and PLPEth are the most abundant
forms (homologues), comprising 37-46% and 26-28% of all the
homologues, respectively. The half life of these 2 homologues
is 4 to 10 days, with a detection window of about 2 to 4 weeks,
depending on the individual.

POPETH and PLPEth are measured by LC-MS/MS.

This test is for monitoring and clinical management of patients.
It is not intended for forensic use.

If applicable, any drug confirmation testing reported
here was developed and the performance characteristics
determined by Warde Medical Laboratory. This
confirmation testing has not been cleared or approved
by the FDA. The laboratory is regulated under CLIA as
qualified to perform high-complexity testing. This test
is used for patient testing purposes. It should not be

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,

D826001956

Ordered By: CLIENT C CLIENT,

WX0000073111

WX00000000409391

Report Date: 06/26/2026 15:11

WMB-26-367496

Page 1 of 2

Kajal V. Sitwala, MD, PhD - Medical Director



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000073111 F 02/15/1985

regarded as investigational or for research.

Performing Site:
WMRL: Warde Medical Laboratory 300 West Textile Road Ann Arbor MI 48108 (800)876-6522

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,
D826001956 Ordered By: CLIENT C CLIENT,
WX0000073111 WX00000000409391

Report Date: 06/26/2026 15:11

WMB-26-367496

Page 2 of 2

Kajal V. Sitwala, MD, PhD - Medical Director

Inactivate Test With Replacement

Effective Date 8/25/2026

Inactivated Test

Name Gabapentin, Urine

Code UGABA

Legacy Code UGABA

Interface Order Code 3515240

Replacement Test

Name Clin Urine Gabapentin Confirm

Code UCGAB

CPT Code(s) 80355 (G0480)

Notes New York DOH Approval Status: No

Specimen Requirements

Specimen Required

Specimen Information: This test is for clinical use only and not intended for employment related testing. See Interface Map for complete list of analytes included.

- Quantitative confirmation.
- This test is designed to detect gabapentin.
- False negative results may occur if drugs are present below the tests limit of detection.
- Potential ordering options
 - Pain confirmation panel that includes gabapentin, PN04C

Collect: Random urine

Specimen Preparation: 10.0 mL urine in a screw capped plastic urine container.

Minimum Volume: 3.0 mL

Transport Temperature: Refrigerated

Rejection Criteria Urine catheter cup (with needle)

Stability

Room temperature: 48 hours

Refrigerated: 14 days

Frozen: 30 days

Performing Information

Methodology Liquid Chromatography - Tandem Mass Spectrometry

Reference Range

Decision Level

Gabapentin: 0.5 µg/mL

Performed Days Monday - Friday

Turnaround Time 2 - 6 days

Performing Laboratory Warde Medical Laboratory

Interface Information

Legacy Code UCGAB

Interface Order Code 3000457

Result Code	Name	LOINC Code	AOE/Prompt
3000464	Gabapentin	59680-9	No
3000949	Creatinine	2161-8	No
3000951	Adulterant	58715-4	No



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000007120 F 01/01/1985

Collected: 06/26/2026 11:34

Received: 06/26/2026 11:34

Clinical Gabapentin Confirm

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
Gabapentin	>250	H	Negative	µg/mL	WMRL
Creatinine	80		20-250	mg/dL	WMRL
Adulterant	Negative				WMRL

Confirmation (LC/MS/MS) Decision Limits
Gabapentin 0.5 µg/mL
Adulterant Decision Limit:
General Oxidants 200 ug/mL

The adulterant assay tests for General Oxidants, including Chromates and Nitrites. Adulterants are substances either ingested or added directly to a urine specimen to prevent the detection of drug use.

If applicable, any drug confirmation testing reported here was developed and the performance characteristics determined by Warde Medical Laboratory. This confirmation testing has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for patient testing purposes. It should not be regarded as investigational or for research.

Performing Site:

WMRL: Warde Medical Laboratory 300 West Textile Road Ann Arbor MI 48108 (800)876-6522

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,

D826000667

Ordered By: WILLIAM G FINN,

WX0000007120

WX00000000466359

Report Date: 06/26/2026 11:45

WMB-26-366873

Page 1 of 1

Kajal V. Sitwala, MD, PhD - Medical Director

Inactivate Test With Replacement

Effective Date 8/25/2026

Inactivated Test

Name Methylphenidate and Metabolite, Urine

Code UMPDM

Legacy Code UMPDM

Interface Order Code 3300320

Replacement Test

Name Clin Urine Methylphenidate and Ritalinic Acid Confirm

Code UCMPD

CPT Code(s) 80360 (G0480)

Notes New York DOH Approval Status: No

Specimen Requirements

Specimen Required

Specimen Information: This test is for clinical use only and not intended for employment related testing. See Interface Map for complete list of analytes included.

- Quantitative confirmation.
- This test is designed to detect methylphenidate and ritalinic acid.
- False negative results may occur if drugs are present below the tests limit of detection.
- Potential ordering options
 - Pain confirmation panel that includes methylphenidate and metabolite, PN04C

Collect: Random urine

Specimen Preparation: 10.0 mL urine in a screw capped plastic urine container.

Minimum Volume: 3.0 mL

Transport Temperature: Refrigerated

Rejection Criteria Urine catheter cup (with needle). Samples received at room temperature.

Stability

Room temperature: Unacceptable

Refrigerated: 14 days

Frozen: 30 days

Performing Information

Methodology Liquid Chromatography - Tandem Mass Spectrometry

Reference Range

Decision Level

Methylphenidate: 50 ng/mL

Ritalinic Acid: 50 ng/mL

Performed Days Monday - Friday

Turnaround Time 2 - 6 days

Performing Laboratory Warde Medical Laboratory

Interface Information

Legacy Code UCMPD

Interface Order Code 3000459

Result Code	Name	LOINC Code	AOE/Prompt
3000466	Methylphenidate	3809-1	No
3000467	Ritalinic Acid		No
3000954	Creatinine	2161-8	No
3000956	Adulterant	58714-7	No



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000073111 F 02/15/1985

Collected: 06/26/2026 11:51

Received: 06/26/2026 11:51

Clinical Methylphenidate and Ritalinic Acid Confirm

Test Name	Result	Flag	Ref-Ranges	Units	Site
Methylphenidate	>2000	H	Negative	ng/mL	WMRL
Ritalinic Acid	>2000	H	Negative	ng/mL	WMRL
Creatinine	75		20-250	mg/dL	WMRL
Adulterant	Negative				WMRL

Confirmation (LC/MS/MS) Decision Limits

Methylphenidate	50 ng/mL
Ritalinic Acid	50 ng/mL
Adulterant Decision Limit:	
General Oxidants	200 ug/mL

The adulterant assay tests for General Oxidants, including Chromates and Nitrites. Adulterants are substances either ingested or added directly to a urine specimen to prevent the detection of drug use.

If applicable, any drug confirmation testing reported here was developed and the performance characteristics determined by Warde Medical Laboratory. This confirmation testing has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for patient testing purposes. It should not be regarded as investigational or for research.

Performing Site:

WMRL: Warde Medical Laboratory 300 West Textile Road Ann Arbor MI 48108 (800)876-6522

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,

D826000799

Ordered By: CLIENT C CLIENT,

WX0000073111

WX00000000409391

Report Date: 06/26/2026 11:55

WMB-26-366963

Page 1 of 1

Kajal V. Sitwala, MD, PhD - Medical Director

Inactivate Test With Replacement

Effective Date	8/25/2026
-----------------------	-----------

Inactivated Test

Name	Pregabalin, Urine
Code	UPREG
Legacy Code	UPREG
Interface Order Code	3302220

Replacement Test

Name	Clin Urine Pregabalin Confirm
Code	UCPGL
CPT Code(s)	80366 (G0480)
Notes	New York DOH Approval Status: No

Specimen Requirements

Specimen Required	<i>Specimen Information:</i> This test is for clinical use only and not intended for employment related testing. See Interface Map for complete list of analytes included. - Quantitative confirmation. - This test is designed to detect pregabalin. - False negative results may occur if drugs are present below the tests limit of detection. - Potential ordering options - Pain confirmation panel that includes pregabalin, PN04C <i>Collect:</i> Random urine <i>Specimen Preparation:</i> 10.0 mL urine in a screw capped plastic urine container. <i>Minimum Volume:</i> 3.0 mL <i>Transport Temperature:</i> Refrigerated
--------------------------	---

Rejection Criteria	Urine catheter cup (with needle)
---------------------------	----------------------------------

Stability	Room temperature: 48 hours Refrigerated: 14 days Frozen: 30 days
------------------	--

Performing Information

Methodology	Liquid Chromatography - Tandem Mass Spectrometry
--------------------	--

Reference Range	Decision Level Pregabalin: 0.5 µg/mL
------------------------	---

Performed Days	Monday - Friday
-----------------------	-----------------

Turnaround Time	2 - 6 days
------------------------	------------

Performing Laboratory	Warde Medical Laboratory
------------------------------	--------------------------

Interface Information

Legacy Code	UCPGL
--------------------	-------

Interface Order Code	3000458
-----------------------------	---------

Result Code	Name	LOINC Code	AOE/Prompt
3000468	Pregabalin	105953-4	No
3000952	Creatinine	2161-8	No
3000953	Adulterant	58714-7	No



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000073111 F 02/15/1985

Collected: 06/26/2026 11:56

Received: 06/26/2026 11:56

Clinical Pregabalin Confirm

<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
Pregabalin	>5	H	Negative	µg/mL	WMRL
Creatinine	83		20-250	mg/dL	WMRL
Adulterant	Negative				WMRL

Confirmation (LC/MS/MS) Decision Limits
Pregabalin 0.5 µg/mL

Adulterant Decision Limit:
General Oxidants 200 ug/mL

The adulterant assay tests for General Oxidants, including Chromates and Nitrites. Adulterants are substances either ingested or added directly to a urine specimen to prevent the detection of drug use.

If applicable, any drug confirmation testing reported here was developed and the performance characteristics determined by Warde Medical Laboratory. This confirmation testing has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for patient testing purposes. It should not be regarded as investigational or for research.

Performing Site:

WMRL: Warde Medical Laboratory 300 West Textile Road Ann Arbor MI 48108 (800)876-6522

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,

D826000817

Ordered By: CLIENT C CLIENT,

WX0000073111

WX00000000409391

Report Date: 06/26/2026 11:59

WMB-26-366978

Page 1 of 1

Kajal V. Sitwala, MD, PhD - Medical Director